While I have a few reservations, especially with net debt, and slow down in cash flow, I believe this stock is a buy for the long-term investor. They have a unique product with hospitals somewhat dependent on their supply. The Asian opportunities are also promising, and Immulab will be a key driver once their expansion plans are realized in 2024.
The dividend, whilst modest, reflects a positive outlook, and the desire of management to meet shareholder expectations. As I bought in (via Quantum) at a modest price the return is quite adequate, and with good future prospects, I am happy to hold.
Ann: 1H FY23 Results Presentation, page-6
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PGC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
41.5¢ |
Change
0.005(1.22%) |
Mkt cap ! $686.9M | |||
| Open | High | Low | Value | Volume |
| 41.0¢ | 41.5¢ | 41.0¢ | $457.1K | 1.112M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 417437 | 41.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 41.5¢ | 399983 | 7 |
View Market Depth
| Last trade - 16.10pm 20/06/2024 (20 minute delay) ? |
| PGC (ASX) Chart |